Ovid Therapeutics Inc. (OVID) Research
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.
Market snapshot
- Symbol
- OVID
- Price
- $2.27
- Day change
- -6.20%
- Market cap
- $299.4M
- P/E ratio
- -6.93x
- 52-week range
- 0.285-3.105
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
- Analyst price target
- $5.50
Recent news
- AtaiBeckley wins OVID Health Silver Award for patient partnership in psychedelic trials
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) said on Monday it had received the Silver Award in OVID Health's 2026 Patient Participant Index, recognizing its collaboration with the Psychedelic Participant Advocacy Network (PsyPAN) to strengthen participant involvement in psychedelic clinical research. The clinical-stage biotechnology company said the award highlights a multiyear partnership aimed at incorporating the lived experiences of clinical trial participants into the development of mental health treatments.
Peer companies
Recent insider activity
- Greka Anna — A-Award (130000 shares) on 2026-06-15
- Greka Anna — trade (0 shares) on 2026-06-15
- PAPADOPOULOS STELIOS — A-Award (17578 shares) on 2026-04-07
- Friedman Bart — A-Award (8789 shares) on 2026-04-07
- Fitzgerald Kevin Joseph — A-Award (17578 shares) on 2026-04-07
Open Ovid Therapeutics Inc. (OVID) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.